CN104560991B - Micro RNA for preventing and treating human papilloma virus infection and cervical cancer - Google Patents
Micro RNA for preventing and treating human papilloma virus infection and cervical cancer Download PDFInfo
- Publication number
- CN104560991B CN104560991B CN201310470087.4A CN201310470087A CN104560991B CN 104560991 B CN104560991 B CN 104560991B CN 201310470087 A CN201310470087 A CN 201310470087A CN 104560991 B CN104560991 B CN 104560991B
- Authority
- CN
- China
- Prior art keywords
- cervical cancer
- microrna
- preventing
- micro rna
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002679 microRNA Substances 0.000 title claims abstract description 50
- 206010008342 Cervix carcinoma Diseases 0.000 title claims abstract description 26
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title claims abstract description 26
- 201000010881 cervical cancer Diseases 0.000 title claims abstract description 26
- 208000009608 Papillomavirus Infections Diseases 0.000 title abstract description 14
- 208000021145 human papilloma virus infection Diseases 0.000 title abstract description 7
- 108091070501 miRNA Proteins 0.000 title description 36
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 28
- 108700011259 MicroRNAs Proteins 0.000 claims abstract description 17
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 230000006907 apoptotic process Effects 0.000 claims abstract description 12
- 241000700605 Viruses Species 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 7
- 101150071673 E6 gene Proteins 0.000 claims abstract description 6
- 230000035755 proliferation Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 34
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 108700020796 Oncogene Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 239000005089 Luciferase Substances 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 10
- 108700008625 Reporter Genes Proteins 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 239000013613 expression plasmid Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000010867 Hoechst staining Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000699762 Homo sapiens RNA 3'-terminal phosphate cyclase Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 102100029143 RNA 3'-terminal phosphate cyclase Human genes 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 238000012406 Annexin V-FITC/PI double staining Methods 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000003317 double-positive, alpha-beta immature T lymphocyte Anatomy 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091044988 miR-125a stem-loop Proteins 0.000 description 1
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 description 1
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 description 1
- 108091023127 miR-196 stem-loop Proteins 0.000 description 1
- 108091025686 miR-199a stem-loop Proteins 0.000 description 1
- 108091048308 miR-210 stem-loop Proteins 0.000 description 1
- 108091062761 miR-448 stem-loop Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 102220002645 rs104894309 Human genes 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于生物医学技术领域。涉及一种微小RNA，尤其是一种用于预防和治疗人乳头瘤毒感染以及人宫颈癌的微小RNA。经实验证实，本发明中的微小RNA可以直接靶向细胞内的人乳头瘤病毒E6基因，下调其表达，并最终抑制肿瘤细胞的增殖，诱导肿瘤细胞的凋亡。进一步，所述的微小RNA可制备预防和治疗人乳头瘤毒的感染以及由该病毒所引起的宫颈癌的药物。The invention belongs to the field of biomedical technology. It relates to a microRNA, especially a microRNA for preventing and treating human papillomavirus infection and human cervical cancer. Experiments have confirmed that the microRNA in the present invention can directly target the intracellular human papillomavirus E6 gene, down-regulate its expression, and finally inhibit the proliferation of tumor cells and induce the apoptosis of tumor cells. Further, the microRNA can be used to prepare medicines for preventing and treating human papilloma virus infection and cervical cancer caused by the virus.
Description
The technical field is as follows:
the invention belongs to the technical field of biomedicine. Relates to a micro RNA for preventing and treating human papilloma virus infection and human cervical cancer.
Background art:
cervical cancer is the most common malignancy of the female reproductive tract worldwide. Statistically, there are approximately 50 million new cases of cervical cancer worldwide each year, with over 27 million women dying from the disease. In recent years, the morbidity of the traditional Chinese medicine is increasing, the traditional Chinese medicine is younger, and the mortality is also rising. Therefore, the development of new safe and effective therapeutic targets is not slow.
Human Papilloma Virus (HPV) is a non-enveloped double-stranded circular DNA virus with a genome of about 7200-8000bp in length, encodes 6 early proteins (E1, E2, E4, E5, E6, E7) and two late proteins (L1 and L2). According to the carcinogenic risk, the HPV is divided into high-risk type HPV and low-risk type HPV, wherein the high-risk type HPV is related to cervical cancer and severe precancerous lesion, and the low-risk type HPV causes benign lesions such as genital warts. It is now clear that high-risk HPV infection is the direct and primary cause of cervical cancer. Long-term and large-scale clinical epidemiological investigation at home and abroad discovers that over 99 percent of cervical cancer samples have HPV virus infection, wherein HPV16 is the main infection type. After the cervical tissue is infected by the HPV virus, the tissue usually undergoes a long-term and slow process, generally more than ten years or even decades, and then becomes cancerous. Therefore, in the long-term persistent HPV infection process, the search for targets of resisting HPV infection and virus oncogenes thereof can block the persistent HPV infection and tissue canceration, and is the key for preventing and treating cervical cancer.
microRNA (microRNA, miRNA) is a single-stranded small non-coding RNA with the length of about 19-25 nt, is usually combined with a3 'untranslated region of a target gene, and can also be combined with a 5' untranslated region or a coding region in some cases to degrade mRNA of the target gene or inhibit the translation of the mRNA, so that the gene expression is negatively regulated and controlled at the post-transcriptional level. mirnas are widely present in cells from plants, nematodes to humans, and are involved in regulating a range of vital activities. Up to now, a total of 21264 mature miRNAs found in various species are included in the miRBase database, of which 2042 are found in humans and have been experimentally confirmed (Release19: August 2012). Recent studies show that mirnas are closely related to various malignant tumors, can play the role of oncogenes or cancer suppressor genes, and play an important role in the processes of tumor angiogenesis, tumor cell proliferation, apoptosis, infiltration, metastasis and the like.
In recent years, there is increasing evidence that mirnas have direct antiviral effects. From 2005 to date, multiple human cell mirnas have been reported to directly target and attack exogenous pathogenic viruses, regulating viral gene expression, such as: miR-196 and miR-448 are resistant to HCV virus; miR-199a, miR-210 and miR-125a resist HBV virus; and a series of miRNAs resisting HIV, H5N1, H1N1 virus and the like. This mode of action has been shown to play an important role in the immunity of the body against viral infections. Due to the endogenous and relative safety of miRNA, the characteristic of targeting attack on exogenous virus is utilized to develop corresponding medicine or method, so that the antiviral immunity of an organism can be simulated, and a new opportunity is brought for preventing and/or treating malignant diseases (such as hepatitis C, hepatitis B, AIDS and the like) induced by virus infection.
However, cervical cancer is one of malignant tumors clearly related to viral infection, and no document reports that a certain miRNA can directly target HPV virus and regulate the expression of HPV virus genes so far. No human miRNA is applied to resisting HPV virus. The blockage of HPV persistent infection is the key to the prevention and treatment of cervical cancer.
The invention content is as follows:
in view of the above technical background, the present invention aims to provide a novel therapeutic target and method for treating HPV infection and cervical cancer.
The invention provides a micro RNA nucleic acid sequence for preventing and treating human papilloma virus infection and cervical cancer caused by the virus, which comprises the following specific steps: 5 'UAUACCUCAGUUUUAUCAGGUG 3'. In one embodiment of the present invention, the microRNA can target the 209 th 231nt of the human papillomavirus E6 gene, and the sequence of the 209 th 231nt is: 5 'CAGTTACTGCGACGTGAGGTATA 3'.
The invention also relates to application of the micro RNA, various carriers and pharmaceutical compositions thereof in medicaments for preventing and treating HPV virus infection and cervical cancer caused by the virus.
The pharmaceutical composition contains an effective amount of the nucleic acid sequence and a pharmaceutically acceptable excipient.
In the invention, the human papilloma virus can cause high-risk subtypes of human cervical cancer, including: HPV16, HPV18HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73, HPV 82.
In addition, the invention also relates to the use of the nucleic acid sequence, the vector or the pharmaceutical composition provided by the invention for regulating the expression of the HPV E6 gene.
In the invention, the micro RNA can reduce the expression of human papilloma virus E6 gene, and finally inhibit the proliferation of tumor cells and induce the apoptosis of the tumor cells.
The invention predicts the nucleic acid sequence of the micro RNA by a bioinformatics method. Furthermore, the micro RNA and the predicted target sequence thereof are respectively cloned in a dual-luciferase reporter gene vector, and the result shows that the activity of the reporter gene is obviously inhibited, thereby proving that the micro RNA can directly act with the target. In order to evaluate the influence of the microRNA on the growth of the HPV 16-infected cervical cancer cells, the microRNA expression plasmid is transfected into an HPV 16-positive cervical cancer SiHa cell strain, and the results of a flow cytometry detection method, a Hoechst staining method and a Roche cell analyzer detection method show that the exogenous up-regulation of the expression of the microRNA in cells can obviously slow down the cell proliferation and increase the cell apoptosis, so that the microRNA-mediated silencing effect on HPV virus can interfere the growth fate of tumor cells. Meanwhile, the result of the RT-PCR method shows that the mRNA expression of the E6 oncogene is obviously reduced. Therefore, the invention proves that the micro RNA can directly target and attack the HPV16 virus by targeting the HPV16-E6 gene to influence the carcinogenic capacity of the virus, thereby effectively inhibiting the growth of cervical cancer cells and inducing the apoptosis of the cervical cancer cells. In view of the endogenesis and relative safety of miRNA, if the miRNA is applied to medicines, the miRNA simulates the antiviral immune response generated by the immune system after human cells are infected by HPV, and is expected to become a novel method and element for preventing and treating HPV infection and cervical cancer caused by HPV infection.
Description of the drawings:
FIG. 1: the micro RNA sequence is cloned in a pSilencerr4.1-CMV vector, the predicted target sequence is cloned in a psiCheck-2 vector, and the two recombinant plasmids are co-transfected in HPV negative cervical carcinoma C33A cells to form an experimental group; the blank plasmid and the target fluorescent reporter gene plasmid were cotransfected with C-33A cells as a control group. FIG. 1 shows luciferase activity detected 48 hours after transfection: the fluorescence activity of the experimental group is reduced by 50.918 percent compared with that of the control group, the expression of the reporter gene is obviously inhibited, and the data have statistical significance (P < 0.001)
FIG. 2: transfecting the micro RNA expression plasmid (pSilencer4.1-miRNA-CMV) into an HPV16 positive cervical cancer SiHa cell strain to form an experimental group; SiHa cells transfected with untransfected plasmid and blank plasmid are used as a normal control group and a negative control group. FIG. 2 shows the results of flow cytometry for apoptosis rate: the early apoptosis rate of the experimental group is respectively 4.9 times and 4.2 times of that of the normal control group and the negative control group, the late apoptosis rate is respectively 19.5 times and 21.3 times, the total apoptosis rate is respectively 11.0 times and 10.3 times, and the difference has statistical significance (P is less than 0.05).
FIG. 3: shows the results of detecting SiHa apoptotic cells by Hoechst staining method: the cell fluorescent staining positive rate of the experimental group transfected with the micro RNA expression plasmid is 65.5 times and 36.2 times of that of the normal control group and that of the negative control group respectively. The difference was statistically significant (P < 0.001).
FIG. 4: cell growth curves plotted against SiHa cell proliferation index monitored by Roche xcellife RTCA DP cytoanalyzer are shown: the cell proliferation indexes of the experimental group transfected with the micro RNA expression plasmid are obviously reduced compared with those of a normal control group and a negative control group, and the difference has statistical significance (P is less than 0.05); the cell growth curve shows that the cell proliferation and expansion capability of the experimental group is obviously inhibited.
FIG. 5: and detecting the mRNA expression level of HPV16 virus E6 oncogene in SiHa cells by using an RT-PCR method. FIG. 5 shows the result of electrophoresis bands detected by RT-PCR: after the cells of the experimental group are transfected with the micro RNA expression plasmid, the expression quantity of E6mRNA is obviously reduced.
FIG. 6: the results of grey value analysis of the RT-PCR electrophoretic bands are shown: the expression level of E6mRNA of the experimental group transfected with the micro RNA expression plasmid is reduced by 26.08 percent and 26.60 percent compared with that of the normal control group and the negative control group, and the data are statistically different (P is less than 0.05); the expression level of the control GAPDH has no obvious change and no statistical difference with the control group.
The specific implementation mode is as follows:
example 1
1. Plasmid construction:
designing an amplification primer according to a pri-hsa-miRNA precursor sequence, obtaining a first strand DNA by a DNA synthesis technology, obtaining a double-strand DNA by PCR amplification, and connecting the double-strand DNA into a pSilencer4.1-CMV vector; BamHI and HindIII are used for double enzyme digestion of the miRNA amplified fragment and the psilene 4.1-CMV vector respectively to construct the micro RNA expression plasmid. Oligo primers were designed based on the corresponding target site information and fragments containing the microRNA target sequence were ligated into the psi-check2 vector. XhoI and NotI are used for respectively carrying out double enzyme digestion on the amplified fragment of the target sequence and a psi-check2 luciferase double-reporter gene vector to construct a micro RNA target sequence expression fluorescent reporter gene plasmid. And then transforming E.coli DH5 alpha host bacteria, and performing sequencing identification and concentration determination on the extracted plasmid. The bioinformatics method is adopted to predict that the micro RNA can target a segment of sequence in the E6 gene region in HPV16, wherein the specific position is 209-231nt, and the sequence is as follows: 5 'CAGTTACTGCGACGTGAGGTATA 3'
2. Cell culture and transfection:
the C-33A cells and SiHa cells were cultured in MEM containing 10% by volume fetal bovine serum and cultured in a 5% CO2 incubator at 37 ℃. On the day before transfection, cells were trypsinized and plated in 24-well plates. Preparing a mixed solution of the micro RNA expression plasmid and the corresponding target luciferase reporter gene plasmid, and mixing the mixed solution with LipofectamineTM2000 dilutions were mixed and added to a 24-well plate inoculated with C-33A cells, and after 6 hours, the plate was replaced with MEM containing 10% fetal bovine serum to prepare an experimental group. The blank vector plasmid and the target luciferase reporter gene plasmid were co-transfected into C-33A cells according to the same method as a negative control. Mixing LipofectamineTM2000 dilution and micro RNA plasmid dilution were mixed, added to SiHa cell inoculated plate wells, and changed to 10% fetal bovine serum MEM after 6 hours, to obtain experimental groups. The blank plasmid was transfected into SiHa cells as a negative control, and SiHa cells without plasmid transfection were a normal control. After 24 hours, cell culture supernatants were collected for testing. The above steps are repeated for three times.
3. Luciferase dual reporter system detection luciferase activity:
the transfected C-33A cells were cultured for 24 hours and then lysed. Adding 100 mul of luciferase test reagent II and 20 mul of cell lysate into a detection tube of a chemiluminescence analyzer, uniformly mixing, placing into the chemiluminescence analyzer, detecting the expression quantity of internal reference reporter gene luciferase (namely firefly luciferase), reading the numerical value and recording as F1. Then 100. mu.l of Stop & Glo working solution is added, the solution is evenly blown and stirred, the expression level of the main reporter gene luciferase (namely renilla luciferase) is detected, and the value is read and recorded as F2. The F2/F1 ratio is the luciferase activity obtained. The statistical software SPSS Statistics V20.0 is used to perform normality and homogeneity of variance tests on all data, and variance analysis is used to compare differences among groups.
Detecting SiHa apoptosis rate by an Annexin V-FITC/PI double-staining flow cytometer:
Hoechst staining to detect SiHa apoptotic cells:
SiHa cells were washed three times with PBS 24hr after transfection. 0.5ml of 4% paraformaldehyde was fixed and 0.5ml of Hoechst33258 working solution (10. mu.g/ml) was stained. And (5) sealing the chip by using the anti-fluorescence quenching sealing liquid. The excitation wavelength is 350nm and the emission wavelength is 460nm when observed under a fluorescence microscope.
Detecting SiHa cell proliferation by a Roche cell analyzer:
after SiHa cells were transfected with miRNA plasmid from the beginning of plating, the xcelligene E plate was placed in the xcelligene RTCA DP cell analyzer plate slot every 4hr to detect the cell proliferation index. The cell proliferation index depends on the value of (Rn-Rb)/15 (Rn is the resistance of the bottom electrode of the plate on which cells grow; Rb is the resistance of the bottom electrode of the background plate containing only culture solution). Monitoring for 120hr, and plotting cell proliferation curve. And (4) performing normality and homogeneity of variance tests on each group of data, and comparing differences among the groups by using variance analysis.
RT-PCR method for detecting E6mRNA expression:
and extracting total RNA of the transfected cells to perform reverse transcription polymerase chain reaction. E6 has upstream primer sequence of 5'AGCGACCCAGAAAGTTACCA3' and downstream primer sequence of 5'GCATAAATCCCGAAAAGCAA3' and amplification length of 134 bp. GAPDH was used as an internal reference. The PCR reaction conditions are pre-denaturation at 94 ℃ for 3min, denaturation at 94 ℃ for 30s, annealing at 50 ℃ for 40s, extension at 72 ℃ for 1min, and final extension at 72 ℃ for 10min after 30 cycles. The product was subjected to agarose gel electrophoresis. The TotalLab100 software analyzed the strip.
SEQUENCE LISTING
<110> affiliated obstetrical and gynecological hospital of double-denier university
<120> microRNA for preventing and treating human papilloma virus infection and cervical cancer
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 22
<212> RNA
<213> Artificial
<400> 1
uauaccucag uuuuaucagg ug 22
<210> 2
<211> 23
<212> DNA
<213> Artificial
<400> 2
cagttactgc gacgtgaggt ata 23
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310470087.4A CN104560991B (en) | 2013-10-10 | 2013-10-10 | Micro RNA for preventing and treating human papilloma virus infection and cervical cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310470087.4A CN104560991B (en) | 2013-10-10 | 2013-10-10 | Micro RNA for preventing and treating human papilloma virus infection and cervical cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104560991A CN104560991A (en) | 2015-04-29 |
| CN104560991B true CN104560991B (en) | 2021-02-26 |
Family
ID=53078070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310470087.4A Expired - Fee Related CN104560991B (en) | 2013-10-10 | 2013-10-10 | Micro RNA for preventing and treating human papilloma virus infection and cervical cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104560991B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109371021B (en) * | 2018-07-02 | 2022-11-18 | 武汉凯德维斯生物技术有限公司 | Method for treating HPV positive cervical intraepithelial neoplasia by using CRISPR/Cas9 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013078283A1 (en) * | 2011-11-22 | 2013-05-30 | Intermune, Inc. | Methods of diagnosing and treating idiopathic pulmonary fibrosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014509512A (en) * | 2011-03-02 | 2014-04-21 | グルーブ バイオファーマ コーポレイション | Enhanced biodistribution of oligomers |
-
2013
- 2013-10-10 CN CN201310470087.4A patent/CN104560991B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013078283A1 (en) * | 2011-11-22 | 2013-05-30 | Intermune, Inc. | Methods of diagnosing and treating idiopathic pulmonary fibrosis |
Non-Patent Citations (2)
| Title |
|---|
| The E6 Oncoprotein Encoded by Human Papillomavirus Types 16 and 18 Promotes the Degradation of p53;Martin Scheffner et al;《Cell》;19901221;第63卷;摘要 * |
| 人类microRNA has-mir-875-5p与has-mir-3144-3p靶向调控人乳头瘤病毒16型E6基因;李燕云;《第四次全国妇科肿瘤青年医师学术论坛》;20130630;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104560991A (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Laengsri et al. | Cervical cancer markers: epigenetics and microRNAs | |
| Li et al. | Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein | |
| Pett et al. | Integration of high‐risk human papillomavirus: a key event in cervical carcinogenesis? | |
| Wang et al. | microRNAs are biomarkers of oncogenic human papillomavirus infections | |
| Melsheimer et al. | DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri | |
| Hussen et al. | The role of HPV gene expression and selected cellular MiRNAs in lung cancer development | |
| Jiang et al. | Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells | |
| Zhu et al. | MiR-21-5p, miR-34a, and human telomerase RNA component as surrogate markers for cervical cancer progression | |
| Sammarco et al. | Human papillomavirus infections, cervical cancer and MicroRNAs: an overview and implications for public health | |
| Kuner et al. | Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses | |
| Aromseree et al. | Possible contributing role of Epstein-Barr virus (EBV) as a cofactor in human papillomavirus (HPV)-associated cervical carcinogenesis | |
| Lin et al. | Two less common human microRNAs miR-875 and miR-3144 target a conserved site of E6 oncogene in most high-risk human papillomavirus subtypes | |
| Liu et al. | miR-218 functions as a tumor suppressor gene in cervical cancer | |
| Peralta-Zaragoza et al. | HPV‐Based Screening, Triage, Treatment, and Followup Strategies in the Management of Cervical Intraepithelial Neoplasia | |
| Annunziata et al. | Characterization of the human papillomavirus (HPV) integration sites into genital cancers | |
| Choi et al. | The dysregulation of MicroRNAs in the development of cervical pre-cancer—an update | |
| Zhang et al. | Micro ribonucleic acid‐93 promotes oncogenesis of cervical cancer by targeting RAB11 family interacting protein 1 | |
| CN105274111B (en) | A kind of long-chain non-coding RNA lncRNA CRNN and its application | |
| Chen et al. | Viral etiology relationship between human papillomavirus and human breast cancer and target of gene therapy | |
| Amin et al. | Molecular markers predicting the progression and prognosis of human papillomavirus-induced cervical lesions to cervical cancer | |
| CN104560991B (en) | Micro RNA for preventing and treating human papilloma virus infection and cervical cancer | |
| Lin et al. | E6-associated transcription patterns in human papilloma virus 16-positive cervical tissues | |
| Shen et al. | Inhibitory effect and mechanisms of microRNA-146b-5p on the proliferation and metastatic potential of Caski human cervical cancer cells | |
| CN104560992B (en) | It is a kind of to be used to prevent and treat human papilloma virus infection and the Microrna of cervical carcinoma | |
| Poltronieri et al. | State-of-the-Art on Viral microRNAs in HPV Infection and Cancer Development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210226 Termination date: 20211010 |